Shanghai, China

Chengde Wu

USPTO Granted Patents = 29 


 

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 99(Granted Patents)


Location History:

  • Wuhan, CN (2020)
  • Shanghai, CN (2015 - 2024)
  • Jiangsu, CN (2022 - 2024)

Company Filing History:

goldMedal5 out of 230 
 
Glaxosmithkline Intellectual Property Development Limited
 patents
silverMedal4 out of 118 
 
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
 patents
bronzeMedal3 out of 65 
 
Medshine Discovery Inc.
 patents
42 out of 31 
 
Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.
 patents
51 out of 1 
 
Fuijan Cosunter Pharmaceutical Co. Ltd.
 patent
61 out of 5 
 
Hubei Bio-pharmaceutical Industrial Technological Institute Inc.
 patents
71 out of 1 
 
Shenzhen Salubris Pharm Co Ltd.
 patent
81 out of 1 
 
China Resources Biopharmaceutical Company Limited
 patent
91 out of 1 
 
Hangzhou Sciwind Biosciences Co., Ltd
 patent
101 out of 1 
 
Jumbo Drug Bank Co., Ltd.
 patent
111 out of 7 
 
Fujian Akeylink Biotechnology Co., Ltd.
 patents
121 out of 8 
 
Cstone Pharmaceuticals
 patents
131 out of 2 
 
Cstone Pharmaceutical (suzhou) Co., Ltd.
 patents
141 out of 7 
 
Cstone Pharmaceuticals (shanghai) Co., Ltd.
 patents
151 out of 13 
 
Hua Medicine (shanghai) Ltd.
 patents
161 out of 5 
 
Cisen Pharmaceutical Co., Ltd.
 patents
171 out of 2 
 
Qingdao Huanghai Pharmaceutical Co., Ltd.
 patents
181 out of 1 
 
Dongbao Purple Star (hangzhou) Biopharmaceutical Co., Ltd.
 patent
191 out of 3 
 
D3 Bio (wuxi) Co., Ltd.
 patents
201 out of 5 
 
Cgenetech (suzhou, China) Co., Ltd.
 patents
212 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 2015-2025

where 'Filed Patents' based on already Granted Patents

29 patents (USPTO):

Title: Innovations and Contributions of Chengde Wu in Pharmaceutical Patents

Introduction

Chengde Wu, a prominent inventor based in Shanghai, China, has made significant contributions to the field of pharmaceuticals, holding an impressive 24 patents to his name. His innovative work, particularly in the development of therapeutic agents, underscores his dedication to advancing medical science.

Latest Patents

Wu's recent patents reflect his expertise and commitment to combating serious health issues. One of his notable inventions is the development of macrocyclic derivatives acting as XIa factor inhibitors. This patent discloses a class of macrocyclic derivatives along with a preparation method, pharmaceutical compositions containing these derivatives, and their utilization as therapeutic agents. These compounds are particularly aimed at treating and preventing thromboembolisms and other related diseases, highlighting their potential in critical therapeutic applications.

Another significant patent involves a diarylthiohydantoin compound, recognized as an androgen receptor antagonist. This application pertains to a compound that exhibits a strong antagonistic effect on the androgen receptor and demonstrates excellent antitumor capabilities. The invention emphasizes methods of preparation, pharmaceutical compositions, and therapeutic uses for treating cell proliferative diseases mediated by androgens.

Career Highlights

Chengde Wu has worked with renowned organizations throughout his career, including GlaxoSmithKline Intellectual Property Development Limited and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. His experience with these companies has significantly influenced his research and innovation in pharmaceutical sciences.

Collaborations

Throughout his career, Wu has collaborated with notable colleagues such as Shuhui Chen and Tao Yu. These partnerships have fostered an environment of innovation and have contributed to the successful development of his patented inventions.

Conclusion

In summary, Chengde Wu represents a prominent figure in the pharmaceutical patent landscape, with his 24 patents underscoring his innovative contributions to medicine. His work on macrocyclic derivatives and diarylthiohydantoin compounds not only showcases his ability to address pressing medical issues but also reflects the collaborative spirit that defines the field of pharmaceutical development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…